Answers are grounded in this paper and cite their sources.
Objective N/A. Background Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is a distinct inflammatory demyelinating disorder. Pregnancy is considered an immunotolerant; most studies suggest that the relapse rate of demyelinating diseases decreases during pregnancy, with increased relapse rates postpartum. Nonetheless, MOGAD can present for the first time during pregnancy, creating diagnostic and therapeutic dilemmas. Design/Methods We retrospectively reviewed three MOG-IgG–positive patients from two tertiary centers who presented for the first time during pregnancy or the postpartum period. We summarized clinical phenotype, MRI, acute treatments, disease-modifying therapy (DMT), and obstetric outcomes. Results Three patients with confirmed MOG-IgG-associated disease were identified across two tertiary centers. 2 patients presenting with a new diagnosis of MOGAD for the first time during pregnancy and 1 patients presenting in postpartum period. Out of a total of four clinical episodes, two episodes were optic neuritis and the remaining two presentations were transvers myelitis. One of these patients subsequently relapsed five weeks postpartum. Visual outcomes were favorable overall, with recovery to 20/30 or better following immunotherapy. MOG-IgG titers were ≥1:100 in all; MRI findings demonstrated longitudinally extensive spinal cord lesions in two patients, and bilateral T2 hyperintensities of intra- orbital segments of the optic nerve in another. Pregnancy complications were seen in 2 patients including fetal distress requiring urgent cesarean section at 33 + 6 weeks and intrauterine growth restriction (IUGR) with cesarean delivery at 31 weeks. One patient experienced a miscarriage in subsequent pregnancy at 6 weeks followed by an additional pregnancy complicated by gestational diabetes and preterm cesarean delivery. Conclusions This case series highlights an understudied population presenting with new-onset MOGAD during the peripartum period. MOGAD should remain in the differential diagnosis of inflammatory demyelinating events in pregnancy. Prompt diagnosis and therapy are crucial for maximizing recovery, and further research is needed to clarify the relationship between MOGAD and obstetric outcomes.
No takes yet. Share an insight, caveat, or question.
Raj et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: